Osteoporosis International

, 20:1911 | Cite as

Factors influencing the treatment of osteoporosis following fragility fracture

  • L. Bessette
  • S. Jean
  • K. S. Davison
  • S. Roy
  • L.-G. Ste-Marie
  • J. P. Brown
Original Article



Treatment rates of osteoporosis after fracture are very low. Women who suffer a fragility fracture have a greater chance of receiving anti-fracture treatment if they had low bone mineral density (BMD), a fracture at the hip, femur or pelvis, administration of calcium and vitamin D supplements and/or an age ≥60 years.


This investigation identifies the predictors of osteoporosis treatment 6 to 8 months following fragility fracture in women >50 years of age.


In this prospective cohort study, women were recruited 0 to 16 weeks following fracture and classified as having experienced fragility or traumatic fractures (phase 1). Six to 8 months following fracture, women completed a questionnaire on demographic features, clinical characteristics and risk factors for osteoporosis (phase 2). Osteoporosis treatment was defined as initiating anti-fracture therapy (bisphosphonate, raloxifene, nasal calcitonin and teriparatide) after fracture in those previously untreated.


Of the 1,273 women completing phase 1, 1,001 (79%) sustained a fragility fracture, and of these women, 738 were untreated for osteoporosis at phase 1 and completed the phase 2 questionnaire. Significant predictors of treatment included BMD result, fracture site, administration of calcium and vitamin D supplements at the time of fracture and age ≥60 years. All other risk factors for osteoporosis, such as fracture history after the age of 40 years, family history of osteoporosis and comorbidities did not significantly influence the treatment rate.


Physicians largely based their decision to treat on BMD results and not on the clinical event—fragility fracture.


Care gap Determinants Fragility fracture Osteoporosis Treatment predictors 


  1. 1.
    Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S–17S discussion 17S–19SCrossRefPubMedGoogle Scholar
  2. 2.
    Melton LJ 3rd (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18:1139–1141CrossRefPubMedGoogle Scholar
  3. 3.
    Randell A, Sambrook PN, Nguyen TV, Lapsley H, Jones G, Kelly PJ, Eisman JA (1995) Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int 5:427–432CrossRefPubMedGoogle Scholar
  4. 4.
    Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42CrossRefPubMedGoogle Scholar
  5. 5.
    Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179CrossRefPubMedGoogle Scholar
  6. 6.
    Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382CrossRefPubMedGoogle Scholar
  7. 7.
    Doherty DA, Sanders KM, Kotowicz MA, Prince RL (2001) Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int 12:16–23CrossRefPubMedGoogle Scholar
  8. 8.
    van Staa TP, Leufkens HG, Cooper C (2002) Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 13:624–629CrossRefPubMedGoogle Scholar
  9. 9.
    Klotzbuecher CM, Ross PD, Landsman PB, Abbott TAI, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739CrossRefPubMedGoogle Scholar
  10. 10.
    Mallmin H, Ljunghall S, Persson I, Naessen T, Krusemo UB, Bergstrom R (1993) Fracture of the distal forearm as a forecaster of subsequent hip fracture: a population-based cohort study with 24 years of follow-up. Calcif Tissue Int 52:269–272CrossRefPubMedGoogle Scholar
  11. 11.
    Robinson CM, Royds M, Abraham A, McQueen MM, Court-Brown CM, Christie J (2002) Refractures in patients at least forty-five years old. a prospective analysis of twenty-two thousand and sixty patients. J Bone Joint Surg Am 84-A:1528–1533PubMedGoogle Scholar
  12. 12.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, Croix AZL (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077–2082CrossRefPubMedGoogle Scholar
  13. 13.
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124CrossRefPubMedGoogle Scholar
  14. 14.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344–1352CrossRefPubMedGoogle Scholar
  15. 15.
    Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91CrossRefPubMedGoogle Scholar
  16. 16.
    Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, Boff ML, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D, Group ftPS (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109:267–276CrossRefPubMedGoogle Scholar
  17. 17.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, Investigators ftMOoREM (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637–645CrossRefPubMedGoogle Scholar
  18. 18.
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen W, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier P, Wasnich R, Greenwald M, Kaufman J, Chesnut C, Reginster J, Group ftHIPHS (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340CrossRefPubMedGoogle Scholar
  19. 19.
    Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, Bessant J, Brown JP (2007) The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 19:79–86CrossRefPubMedGoogle Scholar
  20. 20.
    Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778CrossRefPubMedGoogle Scholar
  21. 21.
    Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35:293–305CrossRefPubMedGoogle Scholar
  22. 22.
    Levasseur R, Sabatier JP, Guilcher C, Guaydier-Souquieres G, Costentin-Pignol V, Jean-Jacques PY, Hulet C, Vielpeau C, Marcelli C (2007) Medical management of patients over 50 years admitted to orthopedic surgery for low-energy fracture. Joint Bone Spine 74:160–165CrossRefPubMedGoogle Scholar
  23. 23.
    Papaioannou A, Giangregorio L, Kvern B, Boulos P, Ioannidis G, Adachi JD (2004) The osteoporosis care gap in Canada. BMC Musculoskelet Disord 5:11CrossRefPubMedGoogle Scholar
  24. 24.
    Vik SA, Maxwell CJ, Hanley DA (2005) Treatment of osteoporosis in an older home care population. BMC Musculoskelet Disord 6:7CrossRefPubMedGoogle Scholar
  25. 25.
    Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, Bessant J, Brown JP (2007) Recognizing osteoporosis and its consequences in Quebec (ROCQ): Background, rationale, and methods of an anti-fracture patient health-management programme. Contemp Clin Trials 29:194–210CrossRefPubMedGoogle Scholar
  26. 26.
    Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427CrossRefPubMedGoogle Scholar
  27. 27.
    Ingle BM, Eastell R (2002) Site-specific bone measurements in patients with ankle fracture. Osteoporos Int 13:342–347CrossRefPubMedGoogle Scholar
  28. 28.
    Jacobsen D, Sargent J, Atkinson EJ, O'Fallon WM, Melton LJI (1999) Contribution of weather to the seasonality of distal forearm fractures : a population-based study in Rochester, Minnesota. Osteoporos Int 9:254–259CrossRefPubMedGoogle Scholar
  29. 29.
    Kannus P, Palvanen M, Niemi S, Parkkari J, Jarvinen M (2000) Epidemiology of osteporotic pelvic fractures in elderly people in Finland : sharp increase in 1970–1997 and alarming projections for the new millenium. Osteoporos Int 11:443–448CrossRefPubMedGoogle Scholar
  30. 30.
    Khan SA, de Geus C, Holroyd B, Russell AS (2001) Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med 161:1309–1312CrossRefPubMedGoogle Scholar
  31. 31.
    Tromp AM, Smit JH, Deeg DJH, Bouter LM, Lips P (1998) Predictors for falls and fractures in longitudinal aging study Amsterdam. J Bone Miner Res 13:1932–1939CrossRefPubMedGoogle Scholar
  32. 32.
    Kreiger N, Tenenhouse A, Joseph L, Mackenzie T, Poliquin S, Brown JP, Prior JC, Rittmaster RS (1999) The Canadian Multicentre Osteoporosis Study (CaMos): background, rationale, methods. Can J Aging 18:376–387Google Scholar
  33. 33.
    Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2007) Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 18:1109–1117CrossRefPubMedGoogle Scholar
  34. 34.
    Richards JB, Leslie WD, Joseph L, Siminoski K, Hanley DA, Adachi JD, Brown JP, Morin S, Papaioannou A, Josse RG, Prior JC, Davison KS, Tenenhouse A, Goltzman D (2007) Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res 22:228–234CrossRefPubMedGoogle Scholar
  35. 35.
    Abrahamsen B, Vestergaard P, Rud B, Barenholdt O, Jensen JE, Nielsen SP, Mosekilde L, Brixen K (2006) Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study. J Bone Miner Res 21:796–800CrossRefPubMedGoogle Scholar
  36. 36.
    De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338CrossRefPubMedGoogle Scholar
  37. 37.
    Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822CrossRefPubMedGoogle Scholar
  38. 38.
    Siris ES, Simon JA, Barton IP, McClung MR, Grauer A (2008) Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 19:681–686CrossRefPubMedGoogle Scholar
  39. 39.
    Seeman E, Devogelaer JP, Lorenc R, Spector T, Brixen K, Balogh A, Stucki G, Reginster JY (2008) Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23:433–438CrossRefPubMedGoogle Scholar
  40. 40.
    Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM (2005) Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of −1.6 to −2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 80:343–349CrossRefPubMedGoogle Scholar
  41. 41.
    Vanasse A, Dagenais P, Niyonsenga T, Gregoire JP, Courteau J, Hemiari A (2005) Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec. BMC Musculoskelet Disord 6:33CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  • L. Bessette
    • 1
  • S. Jean
    • 2
  • K. S. Davison
    • 1
  • S. Roy
    • 2
  • L.-G. Ste-Marie
    • 3
  • J. P. Brown
    • 1
  1. 1.Department of Medicine, CHUL Research CentreLaval UniversityQuebec CityCanada
  2. 2.Institut National de Santé Publique du QuébecSainte-FoyCanada
  3. 3.Department of Medicine, Centre de Recherche du CHUM, Hôpital Saint-LucUniversity of MontrealMontréalCanada

Personalised recommendations